In diseases such as atherosclerosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), obesity, myocardial infarction, endometriosis, sepsis, acute lung injury (ALI), and inflammatory bowel disease (IBD), METTL3 promotes glycolysis (18, 23–25, 27–29, 35), enhances mitochondrial damage and ROS production (22, 31), and suppresses the TCA cycle and OXPHOS (20, 21, 36) by regulating the m6A modifications of key genes (see Table 1 for details). Here, METTL3 is linked to metabolic dysfunction-associated steatotic liver disease.